STAT November 13, 2024
Elaine Chen

Good morning, lots of news this morning that we’ll get straight into.

Califf: ‘We’ll see what happens’ under Trump

At a cancer research conference yesterday, FDA Commissioner Robert Califf said he’s “disappointed” about the election’s outcome and suggested he’s unsure about the future of the agency under the incoming Trump administration.

The agency’s ability to hire and retain skilled employees may be in jeopardy given Trump ally Robert F. Kennedy Jr.’s hostility to civil servants. Trump has said he plans to give Kennedy, leader of the “Make America Healthy Again” movement, power over health care policy in his administration.

“I’m biased, but I feel like the FDA is at peak performance right now and we’ll just see what happens as...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Biotech startups are built on venture capital. Track funding rounds here.
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
What might a Trump administration mean for the Biosecure Act?
Flagship, Pfizer alliance yields two more startup deals

Share This Article